一分钟看懂
这是一项关于肾细胞癌的I 期研究，登记的药物或干预包括CD70-targeted CAR-T cells，当前状态为已暂停。登记地点显示中国合肥有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
CD70-targeted CAR-T cells · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The 901 Hospital of Joint Logistics Support Force of People Liberation Army · 合肥
公开的入选条件
- 1. Age ≥18 years, regardless of gender;
- 2. Histologically or cytologically confirmed advanced/metastatic solid tumors (tumors with positive CD70 expression, confirmed histopathological ly with IHC 3+ score);
- 3. Failed or intolerant to standard second-line treatments (at least one of the following: tyrosine kinase inhibitors (TKIs), poly(ADP-ribose) polymerase inhibitors (PARPi), anti-angiogenic therapy; disease progression or inability to tolerate surgery, chemoth
- 4. At least one measurable lesion per RECIST 1.1 criteria, with measurable lesions defined as:
- 1. Extranodal lesions with a long axis ≥10mm on CT scan;
- 2. Lymph node lesions with a short axis ≥15mm on CT scan;
- 3. CT slice thickness ≤5mm.
- 5. ECOG performance status of 0-2 ;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07181720；登记信息更新于 2026-09-11。